Entreprise · 01/10/20041 min de lecture
Prospective Grant of Co-Exclusive License: Monoclonal Antibodies Against the IL-2 Receptor Alpha Chain as a Novel Treatment for Multiple Sclerosis
Traduction automatique locale · Langue originale de la source
Résumé
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a co- exclusive license to practice the inventions embodied in U.S. Provisional Patent Application No. 60/393,021, filed June 28, 2002, "Method of Treating Autoimmune Diseases with Interferon-Beta and IL-2R Antagonist" (DHHS ref. no. E-143-2002/0-US-01), International Patent Application No. PCT/US2002/038290, filed November 27, 2002, International Publication No. WO 2004/002500 A1, published January 8, 2004, "Method of Treating Autoimmune Diseases with Interferon-Beta and IL-2R Antagonist" (DHHS ref. no. E-143-2002/0-PCT-02), International Application No. PCT/US2003/020428, filed June 27, 2003, International Publication No. WO 2004/002421 A2, published January 8, 2004, "Method For the Treatment of Multiple Sclerosis" (DHHS ref. no. E-143-2002/0- PCT-04), and U.S. Patent Application No. 10/607,598, filed June 27, 2003, Publication No. U.S. 2004/0109859 A1, published June 10, 2004, "Method For the Treatment of Multiple Sclerosis" (DHHS ref. no. E- 143-2002/0-US-03), and all corresponding foreig